Chapter 2 生物科技 Flashcards

1
Q

Formivirsen

A

CMV infection Antisense Oligonucleotide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rituximab

A

B-cell lymphoma CD20 B-cell antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alemtuzumab

A

CLL 淋巴瘤 CD52

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Trastuzumab

A

Breast Cancer Her2/neu

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cetuximab

A

多發性上皮癌 EGF Receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bevacizumab

A

乳癌,卵巢癌,肺癌 VEGF 內皮因子

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gemtuzumab

A

AML CD33

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Denileukin

A

T-cell 淋巴瘤 interleukin-2 mAb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Ibritumomab

A

B-cell non-hodgkin’s 淋巴瘤 CD28

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Rituximab

A

B-cell non-hodgkin’s 淋巴瘤 CD20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Nofetumomab

A

小細胞肺癌 carcinoma antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Daclizumab

A

CD25 alpha 防排斥

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Basiliximab

A

CD25 alpha + interleukin-2 防排斥

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Muromonab-CD3 (OKT-3)

A

T-cell receptor 防排斥

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Infliximab

A

IBD Crohn’s Anti-TNF-alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Adalimumab

A

IBD, RA Anti-TNF-alpha

17
Q

Efalizumab

A

psoriasis LFA-1 CD11a

18
Q

Alefacept

A

psoriasis kymphocytes CD2

19
Q

Abciximab

A

抗血小板凝集 alphaIIb/betaIII

20
Q

Capromab

A

Prostrate Cancer prostrate protein

21
Q

Palivizumab

A

RSV disease RSV antigens

22
Q

Omalizumab

A

Asthma

23
Q

Southern blotting

A

DNA sequencing

24
Q

Northern blotting

A

RNA sequencing

25
Q

Western blotting

A

Protein complementary antibodies